Skip to main content

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference.

The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1.

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Contacts

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com



Media:

Email: media@evolus.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.72
+0.18 (0.08%)
AAPL  273.35
-0.76 (-0.28%)
AMD  206.66
-0.92 (-0.44%)
BAC  55.10
-0.23 (-0.42%)
GOOG  306.08
-3.24 (-1.05%)
META  647.37
-0.14 (-0.02%)
MSFT  473.79
-1.03 (-0.22%)
NVDA  176.38
+0.09 (0.05%)
ORCL  186.54
+1.62 (0.88%)
TSLA  468.88
-6.43 (-1.35%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.